How to Check If Orlistat Is Real: The Risk Is Inside the Capsule

If you have a strip or bottle of orlistat capsules and you are unsure where it came from, the box is not the part to worry about.

A capsule can be filled with something else entirely and still look exactly as it should. US regulators who tested counterfeit capsules labelled as orlistat found no orlistat in them at all, and instead varying amounts of a different weight-loss drug that India prohibited in 2011. What follows is what a pack inspection can establish, what it cannot, and where to send a pack you do not trust.

Key Takeaways:

• The documented failure mode for counterfeit orlistat is not an empty capsule. It is substitution with a prohibited drug at doses nobody has measured.
• No Indian over-the-counter strength of orlistat has been identified. The lower strength sold without prescription in some other countries does not apply here.
• A pack check can confirm that the components match each other. It cannot confirm what is inside the capsule.
• A prescription, a licensed pharmacy and a dispensing record are more reliable evidence than any feature of the packaging.
• Reports go to the State Drugs Controller with jurisdiction over where the pack was bought, and to the manufacturer using contact details from its official Indian corporate site only.

In 2010 the US Food and Drug Administration tested counterfeit Alli, a product sold in that market as orlistat, and reported that the capsules contained no orlistat and varying quantities of sibutramine. Following the directions printed on that pack could have delivered around three times the usual daily exposure to sibutramine, and roughly twice its recommended maximum.

The agency also described missing lot information, an incorrectly formatted expiry date and physical differences from the genuine article. Those clues belonged to that American pack rather than to anything found in India.

Why sibutramine matters here is pharmacological rather than commercial. India prohibited sibutramine and R-sibutramine formulations through G.S.R. 82(E), dated 10 February 2011. It was withdrawn in the United States after evidence of increased cardiovascular events, and it can raise blood pressure and heart rate.

So the failure mode is not an inert capsule that does nothing for the person who swallows it. It is unknowing exposure to a drug an Indian regulator removed from the market, in an amount nobody has measured.

A common and consequential error is to carry the status orlistat has elsewhere into the Indian context. The lower of its two strengths is sold without a prescription in some other markets, and that has nothing to do with India.

A Rajya Sabha answer of March 2025 records that CDSCO has approved orlistat for weight management in India, and that these medicines are required to be sold in accordance with the Drugs and Cosmetics Act 1940 and its Rules. It does not identify any Indian over-the-counter strength, so the status a pack carries abroad settles nothing about how it may lawfully be sold here.

CDSCO's approval database records orlistat capsules approved to three manufacturers between 2004 and 2009, at two strengths. Those are approval records rather than a register of what is currently on the market. No primary-source CDSCO register establishing a complete, current, brand-by-brand Indian orlistat market could be located.

A brand absent from the approval records is not thereby fake and a brand present in them is not thereby the one in your hand. What carries more weight is the transaction itself: a prescription, a licensed pharmacy and a dispensing entry are evidence a counterfeit pack alone cannot supply.

Start by confirming that the blister or bottle, the inner label and the outer carton agree with one another on product name, strength, manufacturer, manufacturing-licence number, batch number, manufacture date and expiry date.

Where Schedule H labelling applies, the Drugs Rules require the pack to carry the "Rx" symbol and the prescribed caution restricting retail sale to a prescription. Disagreement between any two components is a real finding and worth acting on. Agreement between them is weaker evidence than it feels, because every particular is printed by whoever printed the pack.

What each pack check can and cannot establish:

• Batch number and dates matching across blister, label and carton: Establishes that the pack components are internally consistent. Does not establish that the batch number is genuine, or that the capsule contains orlistat.
• Manufacturer name and licence particulars present: Establishes that the label carries the regulatory information expected of it. Does not establish that the named manufacturer made what is inside.
• "Rx" symbol and Schedule H caution: Establishes that the pack resembles the required prescription presentation. Does not establish chemical identity, or that the supply itself was lawful.
• QR or barcode, where required: Establishes that the code resolves and carries the expected encoded particulars. Does not establish that the capsules have not been substituted.
• Manufacturer confirmation of the batch: Establishes that the batch and pack configuration correspond to company records. Does not establish chain-of-custody integrity after the pack left the factory.
• Laboratory analysis: Establishes the identity and content of the sample submitted. Does not establish anything about capsules that were not in the tested sample.

India's mandatory barcode or QR requirement covers the brands notified under Schedule H2. The absence of a code on a formulation outside that list is not by itself evidence of counterfeiting, and a code that resolves correctly still cannot exclude substitution inside the capsule.

No Indian manufacturer was found to publish capsule, blister or bottle security specifications detailed enough to authenticate an orlistat pack by eye.

Articles on this subject tend to reach for an Indian example, and none is offered above for a reason. No orlistat entry in CDSCO's not-of-standard-quality or spurious-drug lists could be confirmed from primary sources in enough detail to responsibly name a brand, a batch and a specific failure. Naming one on weaker evidence would damage a manufacturer and tell you nothing useful about the pack you are holding.

The distinction between those two lists is worth carrying away in any case, because they are often conflated. A not-of-standard-quality finding means a tested sample failed to meet a specification, which is a narrower conclusion than it sounds. Substitution or false manufacture is a different matter under the Drugs and Cosmetics Act 1940, where a product misrepresenting what it is or who made it falls into the spurious category. The American counterfeit described earlier is an example of the second kind, not the first.

Enforcement of drug sale and distribution in India rests primarily with State Licensing Authorities. A suspected pack goes to the State Drugs Controller with jurisdiction over where it was bought, and that report is more useful when the evidence has survived intact.

Keep the capsules, the blister or bottle, the carton and the transaction record together. Take no further doses, tell the prescriber, and photograph everything before it is handled further.

Approach the manufacturer in parallel, using contact details taken from its official Indian corporate website rather than from the seller, a listing or the pack itself. Send photographs of every face of the pack and of the capsules, along with the batch number, the manufacture and expiry dates, the manufacturing-licence number and the invoice, and ask the specific question: does this batch and this pack configuration match the company's records?

Report any adverse reaction separately through the Indian Pharmacopoeia Commission's Pharmacovigilance Programme of India, because a reaction report and an authenticity complaint are different filings that reach different people.

An orlistat pack of uncertain origin usually points to a more basic question, which is whether a medicine is the right route at all. That question is the one worth taking to a registered medical practitioner, who can assess whether a medicine is indicated and can say plainly when medication is inappropriate for a particular person.

Unsure whether a weight-loss medicine is right for you, or where to obtain it safely? Speak to a Voy clinician before starting or changing anything.

Enforcement of drug sale and distribution in India rests primarily with State Licensing Authorities. A suspected pack goes to the State Drugs Controller with jurisdiction over where it was bought, and that report is more useful when the evidence has survived intact.

Keep the capsules, the blister or bottle, the carton and the transaction record together. Take no further doses, tell the prescriber, and photograph everything before it is handled further.

Approach the manufacturer in parallel, using contact details taken from its official Indian corporate website rather than from the seller, a listing or the pack itself. Send photographs of every face of the pack and of the capsules, along with the batch number, the manufacture and expiry dates, the manufacturing-licence number and the invoice, and ask the specific question: does this batch and this pack configuration match the company's records?

Report any adverse reaction separately through the Indian Pharmacopoeia Commission's Pharmacovigilance Programme of India, because a reaction report and an authenticity complaint are different filings that reach different people.

An orlistat pack of uncertain origin usually points to a more basic question, which is whether a medicine is the right route at all. That question is the one worth taking to a registered medical practitioner, who can assess whether a medicine is indicated and can say plainly when medication is inappropriate for a particular person.

Unsure whether a weight-loss medicine is right for you, or where to obtain it safely? Speak to a Voy clinician before starting or changing anything.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.